Nasdaq · CIK 0001652935
ACTU ACTUATE THERAPEUTICS, INC.
Insider trading from SEC Form 4. Last filing Aug 14, 2026. Close $0.61 on Oct 9, 2026, 0% from the 52-week low and -92% from the high.
ACTUATE THERAPEUTICS, INC. (ACTU) has 25 SEC Form 4 filings on file from 12 insiders, the latest filed on Aug 14, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
4 open-market trades have been scored at ACTU. The newest: Todd S Thomson (director and 10% owner) sold $1.6M of stock on Jan 5, 2026, filed Jan 7, 2026, scored 45 (moderate). 3 insiders bought within 14 days of each other around Jun 27, 2025.
ACTU closed at $0.61 on Oct 9, 2026, 0% above its 52-week low and 92% below its 52-week high.
1 Form 144 notice of planned sales is on file, the latest filed Dec 11, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ACTUATE THERAPEUTICS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | Todd S Thomson director, owner sell | $1.6M 280,000 shares | -24% | +12% from low-47% from high | |
| 58Moderate | Aaron G.L. Fletcher director, owner buy | $500k 71,428 shares | +57% | - | |
| 58Moderate | Leslie W. Kreis director, owner buy | $500k 71,428 shares | +57% | - | |
| 58Moderate | Bios Equity COF, LP director, owner buy | $500k 71,428 shares | +57% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 11, 2025 | Kairos Venture Partners II, L.P. Affiliate | 280,000 1.20% of outstanding | $2.1M | Dec 11, 2025 | none |
Transactions
Every row filed, 35 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Daniel M Schmitt President, CEO and Director | MOption exercise Common Stock | +272,056 | $0.00 | $0 | 422,237 | Aug 14, 2026 |
| Aug 14, 2026 | Daniel M Schmitt President, CEO and Director | FTax withholding Common Stock | -120,521 | $1.01 | $122k | 301,716 | Aug 14, 2026 |
| Aug 14, 2026 | Daniel M Schmitt President, CEO and Director | MOption exercise Restricted Stock Unitsderivative | -272,056 | $0.00 | $0 | 0 | Aug 14, 2026 |
| May 21, 2026 | Dan Zabrowski director | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 15,000 | May 22, 2026 |
| May 21, 2026 | Todd S Thomson director, owner | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 15,000 | May 22, 2026 |
| May 21, 2026 | Roger Sawhney director | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 15,000 | May 22, 2026 |
| May 21, 2026 | Amy L Ronneberg director | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 15,000 | May 22, 2026 |
| May 21, 2026 | Jason A Keyes director | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 15,000 | May 22, 2026 |
| May 21, 2026 | Martin H. Huber Jr. director | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 15,000 | May 22, 2026 |
| May 21, 2026 | Aaron G.L. Fletcher director, owner | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 15,000 | May 22, 2026 |
| Apr 1, 2026 | Paul J Lytle Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +105,000 | $0.00 | $0 | 105,000 | Apr 1, 2026 |
| Apr 1, 2026 | Andrew Paul Mazar Chief Operating Officer | AGrant or award Employee Stock Option (right to buy)derivative | +105,000 | $0.00 | $0 | 105,000 | Apr 1, 2026 |
| Apr 1, 2026 | Daniel M Schmitt President, CEO and Director | AGrant or award Employee Stock Option (right to buy)derivative | +237,000 | $0.00 | $0 | 237,000 | Apr 1, 2026 |
| Feb 13, 2026 | Daniel M Schmitt President, CEO and Director | MOption exercise Common Stock | +272,055 | $0.00 | $0 | 272,055 | Feb 13, 2026 |
| Feb 13, 2026 | Daniel M Schmitt President, CEO and Director | FTax withholding Common Stock | -121,874 | $4.33 | $528k | 150,181 | Feb 13, 2026 |
| Feb 13, 2026 | Daniel M Schmitt President, CEO and Director | MOption exercise Restricted Stock Unitsderivative | -272,055 | $0.00 | $0 | 272,056 | Feb 13, 2026 |
| Jan 5, 2026 | Todd S Thomson director, owner | SOpen-market sale Common Stockindirect: By Kairos Venture Partners II, L.P. | -280,000 | $5.80 | $1.6M | 904,795 | Jan 7, 2026 |
| Jun 27, 2025 | Aaron G.L. Fletcher director, owner | POpen-market purchase Common Stockindirect: Directly held by Bios 2024 Co-Invest, LP | +71,428 | $7.00 | $500k | 196,428 | Jun 30, 2025 |
| Jun 27, 2025 | Bios Equity COF, LP director, owner | POpen-market purchase Common Stockindirect: Directly held by Bios 2024 Co-Invest, LP | +71,428 | $7.00 | $500k | 196,428 | Jun 30, 2025 |
| Jun 27, 2025 | Leslie W. Kreis director, owner | POpen-market purchase Common Stockindirect: Directly held by Bios 2024 Co-Invest, LP | +71,428 | $7.00 | $500k | 196,428 | Jun 30, 2025 |
| Jun 27, 2025 | Leslie W. Kreis director, owner | POpen-market purchase Warrant (Right to Buy)derivativeindirect: Directly held by Bios 2024 Co-Invest, LP | +71,428 | $0.00 | $0 | 71,428 | Jun 30, 2025 |
| Jun 27, 2025 | Aaron G.L. Fletcher director, owner | POpen-market purchase Warrant (Right to Buy)derivativeindirect: Directly held by Bios 2024 Co-Invest, LP | +71,428 | $0.00 | $0 | 71,428 | Jun 30, 2025 |
| Jun 27, 2025 | Bios Equity COF, LP director, owner | POpen-market purchase Warrant (Right to Buy)derivativeindirect: Directly held by Bios 2024 Co-Invest, LP | +71,428 | $0.00 | $0 | 71,428 | Jun 30, 2025 |
| May 22, 2025 | Aaron G.L. Fletcher director, owner | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 15,000 | May 23, 2025 |
| May 22, 2025 | Dan Zabrowski director | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 15,000 | May 23, 2025 |
| May 22, 2025 | Amy L Ronneberg director | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 15,000 | May 23, 2025 |
| May 22, 2025 | Jason A Keyes director | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 15,000 | May 23, 2025 |
| May 22, 2025 | Roger Sawhney director | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 15,000 | May 23, 2025 |
| May 22, 2025 | Todd S Thomson director, owner | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 15,000 | May 23, 2025 |
| Apr 1, 2025 | Paul J Lytle Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +49,394 | $0.00 | $0 | 49,394 | Apr 2, 2025 |
| Apr 1, 2025 | Andrew Paul Mazar Chief Operating Officer | AGrant or award Employee Stock Option (right to buy)derivative | +51,046 | $0.00 | $0 | 51,046 | Apr 2, 2025 |
| Apr 1, 2025 | Daniel M Schmitt President, CEO and Director | AGrant or award Employee Stock Option (right to buy)derivative | +66,503 | $0.00 | $0 | 66,503 | Apr 2, 2025 |
| Apr 1, 2025 | Paul J Lytle Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +41,899 | $0.00 | $0 | 41,899 | Apr 2, 2025 |
| Apr 1, 2025 | Andrew Paul Mazar Chief Operating Officer | AGrant or award Employee Stock Option (right to buy)derivative | +110,346 | $0.00 | $0 | 110,346 | Apr 2, 2025 |
| Apr 1, 2025 | Daniel M Schmitt President, CEO and Director | AGrant or award Employee Stock Option (right to buy)derivative | +204,285 | $0.00 | $0 | 204,285 | Apr 2, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Bios Equity COF, LPowner, director
- Aaron G.L. Fletcherowner, director
- Martin H. Huber Jr.ceo, president, officer, director
- Jason A Keyescfo, officer, director
- Leslie W. Kreisowner, director
- Paul J LytleChief Financial Officer
- Andrew Paul MazarChief Operating Officer
- Amy L Ronnebergdirector
- Daniel M SchmittPresident, CEO and Director
- Roger Sawhneydirector
- Todd S Thomsondirector, owner
- Dan Zabrowskidirector
Questions about ACTU
Answered from the filings on this page, as of the latest one.
Are insiders buying ACTU?
No. In the last 90 days no insider at ACTUATE THERAPEUTICS, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ACTU on the open market?
Todd S Thomson (director and 10% owner) sold $1.6M of ACTU on Jan 5, 2026 and filed the Form 4 on Jan 7, 2026. InsiderTell scored 45 (moderate).
How many insiders file Form 4 at ACTUATE THERAPEUTICS, INC.?
12 people have filed a Form 4 at ACTUATE THERAPEUTICS, INC., among them Bios Equity COF, LP (10% owner and director), Aaron G.L. Fletcher (10% owner and director), Martin H. Huber Jr. (CEO, president and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.